Articles tagged with Brain Tumors
A new treatment approach targets angiogenesis, inflammation, and oxidative stress in glioblastoma multiforme, reducing tumor volume and growth by up to 89%. The combination of LAU-0901, Elovanoids, and Avastin shows promise in improving survival rates for patients with this deadly cancer.
Researchers found low T cell infiltration in glioblastoma tissue, with higher CD8+ TIL density at recurrence. The study suggests that immune checkpoint inhibition may not be effective due to limited tumour-infiltrating lymphocyte density.
Researchers analyzed data from over 3,200 brain metastatic tumors and discovered that different types of cancer tend to spread to specific parts of the brain. The study's findings may help predict where a particular cancer will metastasize and inform treatment strategies.
Researchers discovered that new mutations in the BRAF gene can lead to gliomas growing back after treatment, suggesting personalized approaches to therapy. The study also explored potential impacts of COVID-19 vaccines on menstruation.
A nationwide study of 295,000 brain cancer patients reveals significant differences in survival and incidence based on sex and age. The findings suggest that males have higher incidence rates, while females have longer survival rates at almost every age group, except among children aged 0-9 years.
Scientists at Ann & Robert H. Lurie Children's Hospital of Chicago discovered a surprising link between growth factor receptor PDGFRA and hypomyelination in mouse models. The study suggests that blocking this receptor could be a novel strategy to treat myelination disorders like multiple sclerosis.
Researchers at Uppsala University developed a new method to track individual cancer cells and their offspring over time. The study found that brain tumour cells are hierarchically organised, but with some degree of flexibility, and that drug treatment influences cell organisation. This breakthrough may lead to the development of target...
Researchers develop a novel cell reprogramming strategy to transform glioma cells into non-proliferative neurons. This approach shows promise in slowing down the growth of GBMs and overcoming harmful side effects of conventional treatments.
A team of researchers led by CU Cancer Center member Jean Mulcahy Levy examined tumor samples before and after treatment with a targeted medicine. They found additional mutations that can create resistance to the therapy, highlighting the need for new treatments or combination therapies.
Researchers found that ribociclib achieved pharmacologically-relevant concentrations in tumor tissue, while everolimus showed minimal penetration. The combination is promising for brain cancer treatment and could lead to new therapeutic drug combinations.
Researchers at McGill University identified proteins that drive cancer stem cells in brain tumours. Targeting the protein galectin1 may provide a more effective treatment for glioblastoma when combined with radiation therapy. The study found significant improvement in tumour response to radiation therapy, resulting in expanded lifespan.
A new study has identified the periaqueductal gray as a critical hub for changes in spiritual identification, surprising researchers who previously thought it was associated with higher brain regions. The discovery could have significant implications for understanding spirituality's role in managing physical and emotional pain.
A new study suggests that a treatment for canine glioblastoma may also be effective in humans, with some dogs experiencing significant tumor shrinkage. The treatment uses an immunotherapy drug called STING agonist, which induced a robust immune response against cancer cells.
A study by the Center for Cell-Based Therapy in São Paulo, Brazil, has discovered a set of biomarkers that can be used to predict which patients with glioblastoma may have tumors resistant to radiation therapy. The genetic signature helps doctors choose the best treatment option for these patients.
Researchers at Tel Aviv University successfully printed the first entirely active and viable glioblastoma tumor using a 3D printer. The 3D-bioprinted model includes functional blood vessels that simulate a real tumor, making it a promising tool for predicting treatment efficacy and drug development.
Researchers at Houston Methodist used a helmet generating a noninvasive oscillating magnetic field to treat end-stage recurrent glioblastoma. The treatment resulted in a 31% reduction of the tumor mass, with significant shrinkage appearing to correlate with the treatment dose.
Researchers found that losartan treatment reduced inflammatory signaling and swelling in vestibular schwannomas, preventing hearing loss. The drug also increased oxygen delivery to enhance the effectiveness of radiation therapy, potentially lowering radiation doses needed to control tumor growth.
Researchers studied the mechanism of liposome accumulation in tumors using fluorescent microscopy and imaging. They found that different lipids have varying abilities to accumulate in tumors, with one lipid type showing remarkable extravasation and reaching immune and tumor cells.
Researchers at Uppsala University discovered lymph node-like structures in brain cancer patients where immune cells can be activated. Immunotherapy enhanced these structure formation in a mouse model, suggesting new ways to regulate the anti-tumour response.
A new study reveals similarities between glioblastoma and melanoma, as well as unique immunosuppressive factors specific to glioblastoma microenvironment. This framework can be used to uncover pathophysiological and molecular features that determine the effectiveness of immunotherapies.
ASU engineering researchers have discovered a new neural stem cell state that could be key to unlocking new methods of brain cancer treatment. The team found that the quiescent Neural G0 state is independent of a tumor's proliferation rate and can potentially be targeted for new drug treatments.
A study coordinated by the University of Trento identified the cell of origin of medulloblastoma, a common and aggressive childhood brain cancer. The researchers used organoids, three-dimensional models of tumor tissue, to understand the genetic mechanisms responsible for this type of brain cancer.
A recent study published in Scientific Reports found that carefully considered surgical treatment improves the prognosis for elderly brain tumour patients. Almost half of patients who had ended up in institutional care due to a brain tumour were able to return home thanks to surgery.
Researchers at Nagoya University have developed a simple urine test that can detect brain tumors with high accuracy, using microRNAs as biomarkers. The new device can extract more microRNAs from just a milliliter of urine than conventional methods, and shows promise for early diagnosis and treatment.
A new radiopharmaceutical, 18F-DASA-23, has successfully visualized the 'master switch' protein PKM2 in glioblastoma patients. This allows for non-invasive assessment of treatment response and potential early detection of therapeutic effectiveness.
A British man diagnosed with IDH1-mutant glioblastoma has lived with a growing tumor for over 80 months on a ketogenic diet. Researchers believe this reflects the benefits of using the body's own metabolism to fight cancer, offering a non-toxic alternative to chemotherapy and radiation therapy.
Researchers discover that children with average risk medulloblastoma can receive a smaller volume of radiation boost without reducing survival rates. However, reducing the dose of radiation given to the whole brain and spine over six weeks had a negative impact on survival.
Researchers discovered that neural activity underlying visual signals can ignite and feed tumors in young children with neurofibromatosis type 1. The study found that raising mice in the dark or treating them with an experimental cancer drug slowed tumor growth, suggesting a key role for controlling neuronal activity.
Researchers found that light exposure triggers the formation of brain tumors in genetically prone mice, which could help prevent similar tumors in children at high risk. The study suggests using cool sunglasses or repurposing drugs to block unwanted neuronal activity and reduce tumor growth.
Scientists discover a way to reactivate paralyzed immune cells against IDH-mutant gliomas, leading to improved vaccine effectiveness. The researchers identified the molecular mechanism behind the 'immune paralysis' caused by cancer-promoting metabolic products and found a substance that deactivates a key immune system regulatory molecule.
A research team from the University of Münster has identified a new mechanism regulating cell growth in tuberous sclerosis complex (TSC), which affects one in 10,000 newborns. The study reveals how mutations can disrupt protein binding through a 'burr effect', leading to uncontrolled cell growth and tumour formation.
Researchers at Massachusetts General Hospital have developed a strategy to reprogram regulatory T cells in the brain to attack glioblastoma tumors. By targeting a specific receptor on these cells, they can convert them into tumor-fighting immune cells, offering a possible solution to overcome resistance to immunotherapy.
A team of researchers has developed a delivery system for RNA-based therapy in brain tumors using ultrasound and nanoparticles. The technique allows for increased tumor cell death and reduced harmful protein production, with potential for minimal side effects.
The review highlights focused, high-dose radiation's potential to destroy small tumors with minimal impact on surrounding normal tissue. Researchers aim to tailor radiotherapy to optimize benefits and minimize risks through advanced techniques like stereotactic body radiation therapy and radiosurgery.
A team of researchers from Virginia Tech and City of Hope aim to improve CAR-T cell therapy for glioblastoma multiforme by studying the impact of fluid flow on the treatment's success. They believe they can use fluid flow to encourage T cells to move deeper into tumors and kill invading cancer cells.
A new method called XYZeq allows researchers to map variation across cells in a tissue or tumor, gaining insight into their spatial location and function. The technique enables the analysis of cellular patterns in complex environments like cancerous tumors and other organs.
Researchers found that piperlongumine binds to and inhibits TRPV2 protein, which is overexpressed in glioblastoma, a type of brain cancer. The treatment radically shrank tumors and extended life in two mouse models.
A new biomedical implant, microMESH, has been developed to treat glioblastoma multiforme. The device wraps around tumor masses, delivering drugs in a controlled, prolonged manner, increasing therapeutic efficacy.
Researchers at Linköping University and Medical University of Graz developed an ion pump that can deliver chemotherapy agents like gemcitabine directly into the brain with high precision. This method may provide a more effective treatment for glioblastoma, a type of brain tumor.
Researchers have discovered a new compound, inositol hexaphosphate, that can inhibit the growth of medulloblastoma, a common high-grade brain tumour in children. The finding could lead to improved treatments for this devastating disease, with potential benefits for patients whose tumours are resistant to chemotherapy.
Researchers propose a novel therapeutic strategy combining temozolomide with dianhydrogalactitol to overcome resistance mechanisms in glioblastoma. The combination shows synergistic effects in slowing tumour growth, suggesting a promising new approach for treating aggressive brain tumors.
Researchers at the University of Plymouth have discovered a biomarker, Fibulin-2 (FBLN2), that can distinguish between grade I and II meningioma tumours. This breakthrough could spare surgery for up to 85% of patients with lower-grade tumours, reducing the need for high-risk treatments.
A Northwestern University team developed an experimental drug that crosses the blood-brain barrier and triggers death of tumor cells. The spherical nucleic acid (SNA) drug has shown promise for treating other neurological diseases like Alzheimer's and Parkinson's.
Researchers are developing new treatments for childhood and adult brain cancers, including a potential cure for incurable ependymoma. Advanced imaging strategies and targeted therapies aim to improve treatment outcomes and survival rates for patients with glioblastoma and other aggressive brain tumors.
Researchers have identified a novel method using immune cells in cerebrospinal fluid to predict response to immunotherapy for patients with brain metastases. The analysis reveals similarities between immune cells in cerebrospinal fluid and those in brain metastasis, providing valuable insights into tumor microenvironment characterization.
Researchers developed a second window ICG technique to identify brain metastases during surgery, predicting gross-total resection and progression-free survival. The technique achieved high accuracy in distinguishing tumors from healthy brain tissue.
A new type of ultrasound scan, shear wave elastography, has been shown to detect residual cancerous tissue in the brain more sensitively than traditional methods. The technique, which measures tissue stiffness and stretchiness, could improve surgical outcomes and reduce the risk of tumor recurrence.
A new glioma-targeted nano-therapeutic developed by UH researcher Sheereen Majd delivers the highly toxic anti-cancer drug Dp44mT directly to brain tumor cells, reducing toxicity and improving treatment outcomes.
Researchers at Universitat Autonoma de Barcelona developed a novel 3D microscopy analysis to recreate human glioblastoma features. This new approach provides complete information on tumor blood vessels and immune cell interactions, aiding diagnosis and therapy development.
Researchers are now able to use genomic alterations of tumors to determine prognosis and best treatment options for pediatric brain tumors. This approach has significantly changed the field of neurosurgery, enabling more effective treatment with fewer side effects.
A UK-based study using diffusion weighted imaging and machine learning successfully classified common types of pediatric brain tumors, enabling faster and more accurate diagnosis. This non-invasive method has the potential to treat childhood brain tumors more efficiently with favorable outcomes.
Scientists have identified CD161 as a potential new target for immunotherapy of malignant brain tumors, including glioblastoma. The molecule suppresses the cancer-fighting activity of immune T cells, but blocking its pathway enhances the killing of tumor cells and improves survival rates in animal models.
Researchers develop new strategy to stop glioblastoma cell growth by inhibiting PRMT5 enzyme, leading to cellular senescence and tumor suppression. The study provides hope for treating this deadly brain cancer with a new class of drugs.
A new study mapped glioblastoma in genetic and molecular detail, revealing four distinct immune subtypes and potential targets for therapy. The research identified key signaling hubs, gene expression patterns and protein modifications that drive tumor growth.
A new approach inhibiting SCD and blocking FOSB function blunts acquired resistance and extends survival in mouse models of glioblastoma, with potential applicability to other cancers like melanoma.
A new Position Statement from UK stakeholders highlights the limited evidence supporting routine follow-up brain tumor imaging. Researchers propose future studies to assess cost effectiveness, quality of life, and treatment response to determine the value of interval imaging.
A large study found that prolonged high dose use of cyproterone acetate increases the risk of developing meningioma, a mostly non-cancerous brain tumour. The risk declines after stopping treatment, suggesting a biologically plausible causal relationship.
Researchers at St. Jude Children's Research Hospital published a clinical trial report providing molecular profiling insights into pediatric medulloblastoma. The study confirmed the need for integrated molecular assessment of these tumors, highlighting differences in prognosis based on molecular groups.
A recent study found that recurrent glioblastoma tumors with few mutations respond best to immunotherapy, suggesting a predictive biomarker for survival. The finding could lead to new approaches to enhance the effectiveness of immunotherapies in treating this incurable disease.
A new study found that up to 20% of glioblastomas are fueled by overactive mitochondria, making them potentially treatable with current clinical trial drugs. Researchers discovered four types of brain cancer, including the mitochondrial subtype, which has a slightly better prognosis.